BRAF and colorectal carcinoma: Our findings are thus in line with established pathogenetic evidence in BRAF-mutated, MSI-immune CRC and reinforce the concept of TIGIT as a relevant immunoregulatory checkpoint that may constitute a particularly promising therapeutic target within this molecular subset of CRC.